KRICT (Korea Research Institute of Chemical Technology has developed TS-20003, which has displayed testing results in stopping liver fibrosis by controlling the process of ‘autophagy’. The institute has transferred this technology to Thoth Science Inc.

Thoth Science Inc. and 3 other South Korean biotechnology companies will join the ‘BIO CEO & Investor Conference’ of New York in February 2020, to present their pipelines. Thoth Science Inc. is a company that focuses on diabetes treatment and NASH (Nonalcoholic Steatohepatitis) by utilizing stem cells and the cell encapsulation tool, TheraCyte.